Who are Paclitaxel-albumin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cabazitaxel (XRP6258), Docetaxel (D), Placebo plus Docetaxel, Paclitaxel (Pac), Paclitaxel, Epirubicin, Paclitaxel injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paclitaxel-albumin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Paclitaxel-albumin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paclitaxel-albumin (Paclitaxel-albumin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; nanoparticle chemotherapy. Area: Oncology.

phase 3 Taxane; nanoparticle chemotherapy β-tubulin (microtubule) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Paclitaxel-albumin (Paclitaxel-albumin) — Sun Yat-sen University. Paclitaxel-albumin is a nanoparticle formulation of the chemotherapy drug paclitaxel bound to human serum albumin that stabilizes microtubules and arrests cell division in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Paclitaxel-albumin TARGET	Paclitaxel-albumin	Sun Yat-sen University	phase 3	Taxane; nanoparticle chemotherapy	β-tubulin (microtubule)
Cabazitaxel (XRP6258)	Cabazitaxel (XRP6258)	Sanofi	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
Docetaxel (D)	Docetaxel (D)	BeyondSpring Pharmaceuticals Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin
Placebo plus Docetaxel	Placebo plus Docetaxel	Infinity Pharmaceuticals, Inc.	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)
Paclitaxel (Pac)	Paclitaxel (Pac)	Aravive, Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin / microtubules
Paclitaxel, Epirubicin	Paclitaxel, Epirubicin	Tianjin Medical University Cancer Institute and Hospital	marketed	Chemotherapy combination (taxane + anthracycline)	Microtubules (paclitaxel); Topoisomerase II and DNA (epirubicin)
Paclitaxel injection	Paclitaxel injection	Guangzhou Double Bioproducts Co., Ltd	marketed	Taxane; microtubule stabilizer	β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; nanoparticle chemotherapy class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paclitaxel-albumin — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-albumin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab